Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$32.12 USD
+0.08 (0.25%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $32.03 -0.09 (-0.28%) 7:28 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Tarsus Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 17 | 26 | 57 | 0 | 0 |
Cost Of Goods | 2 | 1 | 2 | 0 | 0 |
Gross Profit | 16 | 25 | 55 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 159 | 88 | 67 | 27 | 4 |
Income After Depreciation & Amortization | -143 | -63 | -12 | -27 | -4 |
Non-Operating Income | 11 | 3 | -2 | 0 | 0 |
Interest Expense | 3 | 2 | 0 | 0 | 0 |
Pretax Income | -136 | -62 | -14 | -27 | -5 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -136 | -62 | -14 | -27 | -5 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -136 | -62 | -14 | -27 | -5 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -145 | -63 | -12 | -27 | -4 |
Depreciation & Amortization (Cash Flow) | -2 | 0 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -143 | -63 | -12 | -27 | -4 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 29.38 | 24.62 | 20.55 | 6.21 | NA |
Diluted EPS Before Non-Recurring Items | -4.62 | -2.52 | -0.67 | -4.32 | NA |
Diluted Net EPS (GAAP) | -4.62 | -2.52 | -0.67 | -4.32 | NA |
Fiscal Year end for Tarsus Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 13.08 | 1.87 | 0.00 | 2.50 |
Cost Of Goods | NA | 1.22 | 0.38 | 0.00 | 0.00 |
Gross Profit | NA | 11.86 | 1.49 | 0.00 | 2.50 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 56.32 | 42.43 | 32.83 | 27.46 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -44.46 | -40.94 | -32.83 | -24.96 |
Non-Operating Income | NA | 3.54 | 2.65 | 2.21 | 2.22 |
Interest Expense | NA | 0.99 | 0.86 | 0.82 | 0.68 |
Pretax Income | NA | -41.90 | -39.15 | -31.42 | -23.42 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -41.90 | -39.15 | -31.42 | -23.42 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -41.90 | -39.15 | -31.42 | -23.42 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 31.94 | 30.62 | 26.82 | 26.74 |
Diluted EPS Before Non-Recurring Items | NA | -1.31 | -1.28 | -1.17 | -0.88 |
Diluted Net EPS (GAAP) | NA | -1.29 | -1.28 | -1.17 | -0.88 |